{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:44:39Z","timestamp":1760298279927},"reference-count":41,"publisher":"Wiley","issue":"S52","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":6749,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1990,11]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Conventional treatment of symptomatic essential thrombocythemia (ET) consists of long\u2010term administration of myelosuppressive cytotoxic agents which, although efficacious in most cases, are associated with leukemogenic potential. Alpha\u2010interferon (IFN) exerts a dose\u2010dependent inhibitory influence on thrombopoiesis through a direct antiproliferative effect on megakaryocytic precursors. Therefore, it may provide a biologic, potentially non\u2010mutagenic alternative to conventional cytotoxic treatments. At daily doses ranging from 1 to 5 M.U., alpha\u2010IFN is efficacious in inducing a hematologic response in most patients with ET. Response to IFN is a gradual process. The median time to hematologic response varies from 1 to 3 months and a significant proportion of patients reach and maintain normal platelet counts with low doses (1\u20133 M.U.\/d). Normalization of marrow megakaryocytosis requires longer treatment (9\u201312 months). Also patients resistant to cytotoxic drugs may respond to alpha\u2010IFN, suggesting a lack of cross\u2010resistance between the two treatment modalities. Side\u2010effects, although not severe, represents a limit to the administration of adequate doses of IFN in about 25% of cases. Once hematologic response has been obtained, both low\u2010dose IFN and cytotoxic drugs are effective as maintenance. The full potentialities of alpha\u2010IFN in ET in combination with cytotoxic drugs or with other cytokines need to be further investigated.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1990.tb00899.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T10:29:32Z","timestamp":1279448972000},"page":"15-21","source":"Crossref","is-referenced-by-count":13,"title":["Therapy of essential thrombocythemia with alpha\u2010interferon: Results and prospects"],"prefix":"10.1111","volume":"45","author":[{"given":"M.","family":"Lazzarino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Torromeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Inverardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. L.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Castello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow P.","year":"1981","journal-title":"Blood"},{"issue":"64","key":"e_1_2_1_3_2","first-page":"179","article-title":"Le trombocitemie","author":"Tura S.","year":"1979","journal-title":"Haematologica"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0308-2261(21)00376-3","article-title":"Thrombocytosis and thrombocythaemia","volume":"12","author":"Murphy S.","year":"1983","journal-title":"Clin Haematol"},{"key":"e_1_2_1_5_2","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S.","year":"1986","journal-title":"Sem Hematol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb01900.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90384-7"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330106"},{"key":"e_1_2_1_9_2","first-page":"1495","article-title":"Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: A Polycythemia Vera Study Group Report","volume":"66","author":"Murphy S.","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V63.1.51.51","article-title":"Therapy of essential thrombocythaemia with thiotepa and chlorambucil","volume":"63","author":"Case DC.","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_11_2","first-page":"1339","article-title":"Efficacy trial of Pipobroman in essential thrombocythemia: A study of 24 patients","volume":"68","author":"Brusamolino E.","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_12_2","first-page":"306","article-title":"Pipobroman therapy of essential thrombocythemia","volume":"37","author":"Mazzucconi MG","year":"1986","journal-title":"Scand J Haematol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_1_14_2","first-page":"156","article-title":"Acute leukemia in polycythemia vera","volume":"23","author":"Landaw SA.","year":"1986","journal-title":"Sem Hematol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198611000-00001"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.12.1296"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830280113"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805193182002"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-6-789"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.5.1280.1280"},{"key":"e_1_2_1_21_2","first-page":"75","article-title":"Treatment of Ph1 positive chronic myelogenous leukemia with interferon alpha\u20102b","volume":"2","author":"Morra E.","year":"1987","journal-title":"New Trends Ther Leuk Lymph"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V72.2.642.642","article-title":"Interferon alpha\u20102b as therapy for ph1\u2010positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent or daily administration","volume":"72","author":"Alimena A.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.234"},{"key":"e_1_2_1_24_2","first-page":"233","article-title":"Treatment for excessive thrombocytosis in myeloproliferative disorders with recombinant interferon alpha\u20102c. (Abstract) Congress of Austrian and German Societies of Hematology and Oncolocy","volume":"51","author":"Linkesch W.","year":"1985","journal-title":"Blut"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226078"},{"key":"e_1_2_1_26_2","first-page":"83","article-title":"Interferon alpha\u20102b in the treatment of Philadelphia\u2010negative chronic myeloproliferative disorders with excessive thrombocytosis","volume":"2","author":"Lazzarino M.","year":"1987","journal-title":"New Trends Ther Leuk Lymph"},{"key":"e_1_2_1_27_2","first-page":"277","article-title":"Recombinant alpha\u20102a interferon (alpha\u2010IFN) in the treatment of essential thrombocythaemia. Preliminary report","volume":"72","author":"Gugliotta L.","year":"1987","journal-title":"Haematologica"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92881-4"},{"key":"e_1_2_1_29_2","first-page":"195","article-title":"Effects of recombinant human interferon alpha on human megakaryocyte and fibroblast colony formation","volume":"1","author":"Han ZC","year":"1987","journal-title":"J Biol Regul Homeost Agents"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V70.4.1173.1173","article-title":"Effect of recombinant interferons alpha and gamma on human bone marrow\u2010derived magakaryocytic progenitor cells","volume":"70","author":"Ganser A.","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04251.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07679.x"},{"key":"e_1_2_1_33_2","first-page":"587","article-title":"Effect of interferon on pluripotent hemopoietic progenitors (CFU\u2010GEMM) derived from human bone marrow","volume":"10","author":"Neuman HA","year":"1982","journal-title":"Exper Hematol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.131.3.1300","article-title":"Comparative analysis of the influences of human gamma, alpha, and beta interferons on human multipotential (CFU\u2010GEMM), erythroid (BFU\u2010E) and granulocyte\u2010macrophage (CFU\u2010GM) progenitor cells","volume":"131","author":"Broxmeyer HE","year":"1983","journal-title":"J Immunol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90005-0"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92625-6"},{"key":"e_1_2_1_37_2","unstructured":"KasparuH. ReisnerR. BernhartM. PittermannE. KriegerO. LutzD.First results of the treatment of essential thrombocythaemia with recombinant alpha\u20102b interferon. Proc. XXII Congress of the International Society of Hematology Milan August 28\u2010September 21988 page 259."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91446-3"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92142-9"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320230"},{"key":"e_1_2_1_41_2","first-page":"31","article-title":"The combination of alpha interferon with other antineoplastic agents","volume":"2","author":"Bernasconi C.","year":"1987","journal-title":"New Trends Ther Leuk Lymph"},{"issue":"2","key":"e_1_2_1_42_2","first-page":"48","article-title":"Alpha interferon: Combinations with other antineoplastic modalities","volume":"14","author":"Bonnem EM.","year":"1987","journal-title":"Sem Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1990.tb00899.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1990.tb00899.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:21:38Z","timestamp":1698016898000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1990.tb00899.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,11]]},"references-count":41,"journal-issue":{"issue":"S52","published-print":{"date-parts":[[1990,11]]}},"alternative-id":["10.1111\/j.1600-0609.1990.tb00899.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1990.tb00899.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,11]]}}}